A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
Clinical trial NCT02536339 · COMPLETED
Trial details
- NCT number
- NCT02536339
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-16
- Primary completion
- 2019-05-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.